

1632



Please type a plus sign (+) inside this box → **+**

(Modified) PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<h1>TRANSMITTAL FORM</h1> <p>(to be used for all correspondence after initial filing)</p>	Application Number	10/029,137	
	Filing Date	December 19, 2001	
	First Named Inventor	Mai H. Nguyen	
	Group Art Unit	1632	
	Examiner Name	Liping Chen	
Total Number of Pages in This Submission	5	Attorney Docket Number	407T-301400US

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"> PTO-1449 form and receipt acknowledgment postcard RECEIVED APR 22 2003 </div>
Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Tom Hunter, Reg. No. 38,498, Quine Intellectual Property Law Group, P.C.
Signature	<i>Tom Hunter</i>
Date	4/15/03

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <u>April 16, 2003</u>			
Typed or printed name	Deborah Berwick		
Signature	<i>Deborah Berwick</i>	Date	April 16, 2003



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:

Assistant Commissioner for Patents,
Washington, D.C. 20231, on April 16, 2003

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By

Deborah Berwick

Deborah Berwick

Attorney Docket No. 407T-301400US
Client Ref. No. 2002-186-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Mai H. Nguyen, et al.

Application No.: 10/029,137

Filed: December 19, 2001

For: IDENTIFICATION OF A NOVEL
ENDOTHELIAL-DERIVED GENE
EG-1

Examiner: Liping Chen

Art Unit: 1632

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

RECEIVED
APR 22 2003
TECH CENTER 1600/2900



Mai H. Nguyen, et al.
Application No.: 10/029,137
Page 2

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits per 37 CFR 1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Tom Hunter
Reg. No. 38,498

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

TH:db

RECEIVED
APR 22 2003
TECH CENTER 1600/2900



Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/029,137
	Filing Date	December 19, 2001
	First Named Inventor	Mai H. Nguyen
	Group Art Unit	1632
	Examiner Name	Liping Chen
	Attorney Docket Number	407T-301400US
Date Submitted	April 16, 2003	


U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	1	FOLKMAN (1995) "Seminars in Medicine of the Beth Israel Hospital, Boston: Clinical Applications of Research on Angiogenesis." <i>The New England Journal of Medicine</i> 333: 1757-1763.	
	2	FOLKMAN (1995) "Angiogenesis in Cancer, Vascular, rheumatoid and Other Disease." <i>Nature Medicine</i> 1: 27-31.	
	3	Genbank accession # AF358829	
	4	Genbank accession # AW735731	
	5	HANAHAN (1997) "Signaling Vascular Morphogenesis and Maintenance." <i>Science</i> 277: 48-50.	
	6	HUANG ET AL. (1997) Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature." <i>Science</i> 275: 547-550.	
	7	KOIVUNEN ET AL. (1999) "Tumor Targeting With a Selective Gelatinase Inhibitor." <i>Nature Biotechnology</i> 17: 768-774.	
	8	LEE ET AL. (1998) Sphingosine-1-Phosphate as a Ligand for the G Protein-Coupled Receptor EDG-1." <i>Science</i> 279: 1552-1555.	
	9	LIU ET AL. (2001) "Human Eudomuchin Is an Endothelial Marker." <i>Biochemical and Biophysical Research Communications</i> 288: 129-136.	
	10	LIU ET AL. (2002) "Identification of a Novel Endothelial-Derived Gene EG-1." <i>Biochemical and Biophysical Research Communications</i> 290(1): 602-612.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/029,137
	Filing Date	December 19, 2001
	First Named Inventor	Mai H. Nguyen
	Group Art Unit	1632
	Examiner Name	Liping Chen
	Attorney Docket Number	407T-301400US
Date Submitted	Apr 16, 2003	

RECEIVED
APR 22 2003
TECH CENTER 1000/2900

11	NARKO ET AL. (1997) "Tumorigenic Transformation of Immortalized ECV Endothelial Cells by Cyclooxygenase-1 Overexpression." <i>The Journal of Biological Chemistry</i> 272: 21455-21460.
12	NERI ET AL. (1997) "Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform." <i>Nature Biotechnology</i> 15: 1271-1275.
13	NGUYEN ET AL. (1996) "Novel Synthetic Analogs of Sialyl Lewis X Can Inhibit Angiogenesis in Vitro and in Vivo." <i>Biochemical and Biophysical Research Communications</i> 228: 716-723.
14	NGUYEN ET AL (1997) "Vascular Expression of E-Selectin Is Increased in Estrogen-Receptors-Negative Brest Cancer." <i>American Journal of Pathology</i> 150: 1307-1310.
15	NGUYEN ET AL. (2000) "The human myoepithelial cell displays a multifaceted anti-angiogenic phenotype." <i>Oncogene</i> 19: 3449-3459.
16	O'REILLY ET AL. (1997) "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth." <i>Cell</i> 88: 277-285.
17	POLVERINI (1996) "Cellular adhesion molecules. Newly identified mediators of angiogenesis." <i>The American Journal of Pathology</i> . 148(4): 1023-1029.
18	SARTIPPOUR ET AL. (2001) "Livistona extract inhibits angiogenesis and cancer growth." <i>Oncoogy Reports</i> 8: 1355-1357.
19	ST. CROX ET AL. (2000) Genes Expressed in Human Tumor Endothelium." <i>Science</i> 289: 1197-1202.
20	SURI ET AL. (1996) "Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis." <i>Cell</i> 87: 1171-1180.
21	THORPE AND BURROWS (1995) "Antibody-directed targeting of the vasculature of solid tumors." <i>Breast Cancer Research and Treatment</i> 36: 237-251.
22	VAZQUEZ ET AL. (1999) "METH-1, a Human Ortholog of ADAMTS-1, and METH-2 Are Members of a New Family of Proteins with Angio-inhibitory Activity." <i>The Journal of Biological Chemistry</i> . 274: 23349-23357.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.